Impact on clinical outcome of the presence of the ITD mutation
| FLT3WT/WT (N = 59) | FLT3ITD/WT and FLT3ITD/− (N = 23) | P | |
|---|---|---|---|
| Clinical outcome | |||
| Percentage of CR | 86 | 77 | 0.33 |
| DFS | |||
| Median (months) | 52a | 8 | 0.03 |
| Percentage of DFS at 12 months (95% confidence interval) | 71 (62, 80) | 39 (29, 48) | |
| Survival | |||
| Median (months) | 46a | 11 | 0.14 |
| Percentage alive at 12 months (95% confidence interval) | 74 (65, 82) | 46 (36, 55) |
a Nonparametric estimate of the median is not available. Tabled value represents the median assuming the survival estimates after the last observation follows an exponential curve.